NCT07701512 Clinical Study to Evaluate the Efficacy of Febuxostat in the Treatment of Conservatively Managed Intracranial Hemorrhage Patients
| NCT ID | NCT07701512 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Tanta University |
| Condition | Intracranial Hemorrhage |
| Study Type | INTERVENTIONAL |
| Enrollment | 46 participants |
| Start Date | 2025-11-20 |
| Primary Completion | 2026-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 46 participants in total. It began in 2025-11-20 with a primary completion date of 2026-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To assess the effect of Febuxostat on clinical outcomes and biomarkers of oxidative stress and inflammation in patients with conservatively managed intracranial hemorrhage.
Eligibility Criteria
Inclusion Criteria: * • Age ≥ 18 years old. * Diagnosed with intracranial hemorrhage confirmed by CT scan. * Managed conservatively regarding clinical guidelines. * Able to provide informed consent or have a legal representative provide consent. Exclusion Criteria: * • Patients with a history of previous brain surgery or significant neurological disorders. * Severe comorbidities (e.g., uncontrolled diabetes, severe cardiac disease). * Allergy or contraindication to febuxostat. * Pregnant or breastfeeding women. * Patients requiring surgical intervention for hematoma evacuation. * Renal impairment with SCr \> 4 * Liver impairment with INR \> 5 * Significant deterioration ( GCS \< 8 )
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07701512 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Intracranial Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07701512 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07701512 currently recruiting?
Yes, NCT07701512 is actively recruiting participants. Contact the research team at Merihanelhadidy9@gmail.com for enrollment information.
Where is the NCT07701512 trial being conducted?
This trial is being conducted at Al Mansurah, Egypt.
Who is sponsoring the NCT07701512 clinical trial?
NCT07701512 is sponsored by Tanta University. The trial plans to enroll 46 participants.